A new, free-to-use database of 14,000 known macrolactones fills a knowledge gap concerning these molecules and could serve as a useful tool for future drug discovery.
An exploratory randomized, controlled study on the safety and efficacy of either lopinavir/ritonavir (LPV/r) or Arbidol--antivirals that are used in some countries against HIV-1 and to treat influenza , respectively--as treatments for COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, suggests that neither drug improves the clinical outcome of patients hospitalized with mild-to-moderate cases of the disease over supportive care.
For more information about coronavirus disease (COVID-19) from Johns Hopkins Medicine, visit hopkinsmedicine.org/coronavirus. For information on coronavirus disease (COVID-19) from around the Johns Hopkins enterprise, including from the Johns Hopkins Bloomberg School of Public Health and The Johns Hopkins University, visit coronavirus.jhu.edu.
Immunotherapy drugs that target a protein called programmed death ligand 1 (PD-L1) on the surface of cancer cells have quickly become a mainstay to treat many forms of cancer, often with dramatic results.
Medications for lupus — a long-term autoimmune disease that occurs when a person’s immune system attacks different parts of their body, including their skin — are currently being explored as a treatment for COVID-19 patients. This may significantly limit access to the drugs by those who depend on it to manage their health conditions.
The University of Utah has awarded $1.3 million in grants to 56 projects that will examine a host of issues arising out of the pandemic. These multidisciplinary projects will not only address ways to prevent and treat the disease, but will also explore how to design better personal protective equipment as well as dampen the long-term effects of physical isolation on domestic violence and mental health.
An analysis revealed that water samples held a cocktail of pharmaceuticals and other compounds, including antibiotics, antifungals, anticonvulsants, anesthetics, antihypertensive drugs, pesticides, flame retardants and more. Not all chemicals were found at every test site.
A team of scientists has identified the binding site where drug compounds could activate a key braking mechanism against the runaway growth of many types of cancer. The discovery marks a critical step toward developing a potential new class of anti-cancer drugs that enhance the activity of a prevalent family of tumor suppressor proteins.
The Arizona Center for Education and Research on Therapeutics (AZCERT), a nonprofit dedicated to the safe use of medicines, is making MedSafety Scan®, a web-based decision support system, available free to medical professionals around the world, especially those treating high risk COVID-19 patients.
Convalescent plasma therapy for COVID-19 patients — an experimental approach of giving a transfusion of plasma collected from a donor who has recovered from COVID-19 to a patient with an active infection — is the focus of a new two-part research initiative at Penn Medicine. Researchers will first collect plasma from people who have recovered from their infection under a donor research protocol. The second part involves conducting clinical trials to test the safety and efficacy of giving that plasma to moderately and severely ill hospitalized patients.
Scientists at Sanford Burnham Prebys Medical Discovery Institute, the University of Hong Kong, Scripps Research, UC San Diego School of Medicine, the Icahn School of Medicine at Mount Sinai and UCLA have identified 30 existing drugs that stop the replication of SARS-CoV-2, the virus that causes COVID-19. The study was placed on bioRxiv (pronounced “bio-Archive”), an open-access distribution service for preprints of life science research.
Scientists have deployed artificial intelligence to identify more of the billions of metabolites that are currently unknown. The small molecules underlie and inform every aspect of our lives, including energy production, the fate of the planet, and our health. “Beast Mode” helps explain how they did it.
COVID-19 patients in a clinical trial at Houston Methodist Hospital are responding quickly to the antiviral drug Remdesivir. Sponsored by Gilead Sciences, Houston Methodist was the fifth site in the U.S. to join the trials and the only trial site in Houston. Its clinicians are encouraged by the results.
Southern Research announced today that it has entered into a strategic collaboration with New York-based Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, to support the development of a vaccine, TNX-1800, against the new coronavirus disease, COVID-19, based on Tonix’s proprietary horsepox vaccine platform.
Newswise Live Expert Panel for April 16, 2020: COVID-19 Updates, Medicine Safety, 3D Printed Ventilators, Exercise in Isolation
The lab is responding to the coronavirus crisis by imaging disease-related biomolecules, developing standards for reliable coronavirus testing and enabling other essential research.
Psilocybin mushrooms have been found to have minimal harmful effects and could potentially benefit those with depression. But they remain illegal even though they offer a groundbreaking alternative to several under-treated psychological conditions.
Scientists across the globe are rushing to find inhibitors of SARS-CoV-2, the new coronavirus behind the COVID-19 pandemic. Some are using computer simulations to identify promising compounds before conducting actual experiments in the lab.
During the COVID-19 pandemic, Johns Hopkins Medicine Media Relations is focused on disseminating current, accurate and useful information to the public via the media. As part of that effort, we are distributing our “COVID-19 Tip Sheet: Story Ideas from Johns Hopkins” every Tuesday throughout the duration of the outbreak.
A new international trial will evaluate whether the use of medications to treat high blood pressure affect outcomes among patients who are prescribed the medication and hospitalized with COVID-19. Investigators will examine whether ACEI or ARBs help to mitigate complications or lead to worse outcomes.
Penn State Health Milton S. Hershey Medical Center has begun enrolling participants in an international clinical trial evaluating an investigational antiviral drug, remdesivir, for treatment of coronavirus disease 2019 (COVID-19).
In the race to identify solutions to the COVID-19 pandemic, researchers at the Department of Energy’s Oak Ridge National Laboratory are joining the fight by applying expertise in computational science, advanced manufacturing, data science and neutron science.
Researchers at UC San Diego recently created a pharmacophore model and conducted data mining of the conformational database of FDA-approved drugs that identifies 64 compounds as potential inhibitors of the COVID-19 protease. Among the selected compounds are two HIV protease inhibitors, two hepatitis C protease inhibitors, and three drugs that have already shown positive results in testing with COVID-19.
An analysis of more than 10,000 gliomas and clinical outcomes reported in Nature by scientists in Boston and Paris found that glioma patients whose tumors were hypermutated actually had no significant benefit when treated with checkpoint blockers.
UGA medication experts answer common questions they're receiving from patients
UCLA researchers identify a possible new drug that could help prevent cognitive decline in people who undergo radiation therapy for brain tumors.
Berkeley Lab's Advanced Light Source X-ray facility has been recalled to action to support research related to COVID-19, the coronavirus disease that has already infected about 2 million people around the world.
Irvine, Calif., April 14, 2020 — Four professors at the University of California, Irvine – historian Mark LeVine, scientist Andrej Lupták, sculptor Jennifer Pastor and journalist Amy Wilentz – have been named 2020 Guggenheim Fellows. Jennifer Pastor. UCI The faculty members were among 175 U.S. and Canadian scholars, researchers, artists and writers chosen by the John Simon Guggenheim Memorial Foundation from a pool of nearly 3,000 applicants.
KU Medical Center is one of 60 sites across the nation that will be participating in this clinical trial, led by the Duke Clinical Research Institute.
Scientists at the University of Alberta have shown that the drug remdesivir is highly effective in stopping the replication mechanism of the coronavirus that causes COVID-19, according to new research published today in the Journal of Biological Chemistry.
Clinicians grappling with the pharmacologic management of COPD in patients complaining of exercise intolerance or dyspnea now have new guidance. The American Thoracic Society has published an official clinical practice guideline in which a panel of experts strongly recommended LABA/LAMA combination therapy over LABA or LAMA alone. The complete guideline detailing all the recommendations was posted online ahead of print in the American Journal of Respiratory and Critical Care Medicine.
Cancer cells avoid an immune system attack after radiation by commandeering a cell signaling pathway that helps dying cells avoid triggering an immune response, a new study led by UTSW scientists suggests.
In a small group of patients hospitalized with severe complications of COVID-19 and treated with the experimental antiviral drug remdesivir, clinical improvement was observed in 68% of patients treated, according to an analysis co-authored by Jonathan Grein, MD, director of Hospital Epidemiology at Cedars-Sinai.
Seizure control is the primary driver of epilepsy treatment. For many people with epilepsy, however, the seizures themselves are secondary to what comes after: fatigue, memory loss and other issues that dramatically affect their lives.
EAST LANSING, Mich. – In late January, as the world watched the growing COVID-19 epidemic with increasing unease, a Michigan State University laboratory, which specializes in the use of artificial intelligence and big data to discover therapeutics for cancers, switched gears to face the coming challenge. The Chen Lab, led by Bin Chen, assistant professor in the Department of Pediatrics and Human Development, and the Department of Pharmacology and Toxicology, put its expertise to work.
Researchers at Yale Cancer Center (YCC) have found that use of the checkpoint inhibitor pembrolizumab can extend life with very few side effects in this patient population.
Researchers from Intermountain Healthcare and University of Utah Health in Salt Lake City have launched two vital clinical trials to test the effectiveness and safety of two drugs – hydroxychloroquine (HCQ) and azithromycin – to treat patients with COVID-19.
Physician-scientists at Beth Israel Deaconess Medical Center are now enrolling patients in a clinical trial to evaluate a potential treatment of patients with COVID-19. Part of a multi-site investigation, the trial is evaluating the safety and efficacy of sarilumab, a biologic medication already approved for adults with moderately to severely active rheumatoid arthritis, for the treatment of COVID-19.
In an article published recently in the journal Vaccine, two researchers in the Texas Tech University Department of Psychological Sciences suggest some people find vaccines risky because they overestimate the likelihood of negative events, particularly those that are rare.
The Food and Drug Administration has approved solutions created by scientists at The Ohio State University Wexner Medical Center that both expand and accelerate COVID-19 testing across Ohio.
Scientists at the Icahn School of Medicine at Mount Sinai have discovered a new role for the brain chemical dopamine that is independent of classic neurotransmission. The new role appears to be critical to changes in gene expression related to chronic exposure to, or abuse of, cocaine, according to a study published Friday, April 10, in the journal Science.
A study examining MW189 in healthy adult volunteers was performed by a collaborative team from the University of Kentucky, Duke University and Northwestern University. The work by Van Eldik and the rest of the team is substantial as it is the first time MW189 had been tested in humans.
Research is underway at The University of Texas at El Paso’s School of Pharmacy to develop vaccines and antiviral drugs to combat the novel coronavirus within 15 months to two years.
Novel 'learning while doing' clinical trial approach called REMAP helps doctors find the optimal trade-off between quickly adopting new therapies during a pandemic, such as the anti-malarial drug hydroxychloroquine, and waiting until they are tested in longer clinical trials. The trial announced today at UPMC, called UPMC-REMAP-COVID19 learns from similar trials enrolling around the world and uses artificial intelligence to quickly arrive at answers.
Washington University School of Medicine in St. Louis is launching a clinical trial for patients hospitalized with COVID-19 at Barnes-Jewish Hospital. The trial will investigate the effectiveness of different combinations of the antimalarial drugs chloroquine and hydroxychloroquine and the antibiotic azithromycin in treating ill patients infected with the novel coronavirus.
Researchers from Intermountain Healthcare and University of Utah Health in Salt Lake City have launched two vital clinical trials to test the effectiveness and safety of two drugs –hydroxychloroquine (HCQ) and azithromycin – to treat patients with COVID-19 (infection with the novel coronavirus).
Researchers are using the computing power of thousands of computers in classrooms across Kentucky to identify drugs to treat COVID-19. The desktop computers are part of the DataseamGrid, a network of computers housed in classrooms of 48 Kentucky school districts.
The San Diego Supercomputer Center at the University of California San Diego is providing priority access to its high-performance computer systems and other resources to researchers advancing our understanding of the virus and efforts to develop an effective vaccine in as short a time as possible.
Plant-derived chemicals called cardenolides – like digitoxin – have long been used to treat heart disease, and have shown potential as cancer therapies. But the compounds are very toxic, making it difficult for doctors to prescribe a dose that works without harming the patient. Researchers now show that the wormseed wallflower could be used as a model species to elucidate how plants biosynthesize cardenolides, knowledge that could aid the discovery and development of safer drugs.
Research findings suggest gut microbes can effect allergic immune responses. Tasuku Ogita who has recently joined Shinshu University is an expert on teas and their effects on gut bacteria.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right